A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

Open to people ages 18 years and up

• ≥18 years old
• Locally-advanced or metastatic solid tumor with KRAS G12D mutation
• Disease progression on prior standard treatment, intolerance to or ineligibility for standard treatment, or no available standard treatment to improve the disease outcome
• Cohort specific requirements as follows:
  • Part 1A: Histologically or cytologically confirmed malignant solid tumor of any tissue origin
  • Part 1B
    • Disease group 1: diagnosis of PDAC
    • Disease group 2: diagnosis of CRC
    • Disease group 3: diagnosis of NSCLC
    • Disease group 4: diagnosis of other advanced solid tumor and not part of Disease groups 1, 2 and 3
  • Parts 2A and 2B
    • Combination 1: Diagnosis of CRC or CRC
    • Combination 2: Diagnoses of PDAC, CRC or NSCLC
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

• Prior treatment with any KRAS G12D inhibitor
• Known additional invasive malignancy within 1 year of the first dose of study drug
• History of organ transplant, including allogeneic stem cell transplantation
• Significant, uncontrolled medical condition
• History or presence of an ECG abnormality
• Inadequate organ function

Other protocol-defined Inclusion/Exclusion Criteria may apply